



ASX Announcement

30 September 2021

Date of AGM and Closing Date for Director Nominations

In accordance with ASX Listing Rule 3.13.1, **Invex Therapeutics Limited** (ASX: IXC) (**Company**) advises that the Annual General Meeting of the Company will be held on Thursday, 25 November 2021.

A notice of meeting for the Annual General Meeting is being prepared by the Company and will be announced to ASX and provided to Shareholders in October 2021.

An item of business at the Annual General Meeting will be the election of Directors. The closing date for the receipt of nominations for the election of Directors is Thursday, 7 October 2021.

Any nominations must be received no later than 5:00pm (Perth time) on Thursday, 7 October 2021 at the Company's registered office.

This release dated 30 September has been authorised for lodgement to the ASX by Narelle Warren, Company Secretary

ENDS

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.